CPC of America, Inc. announced that it is actively pursuing the development of proprietary polyethylene glycol (PEG) synthetic sealants as part of its global commercialization strategy for MedClose. MedClose is an investigational-stage vascular closure system that is intended to seal arterial puncture sites following diagnostic or interventional catheterization procedures. CPC will develop synthetic PEG sealants as platform technologies for the MedClose vascular closure system using ultra-pure functionalized, biocompatible and biodegradable polymers. The sealants will have adjustable physical properties, making it possible to fine tune the gel time and strength for varied clinical applications. The proprietary compounds will be sourced from multiple suppliers, providing flexibility and accessibly for global commercialization and cost savings. "PEG sealants have been found to have notable advantages to other surgical sealants,” notes Dr. Olexander Hnojewyj, a medical advisor to CPC who has conducted extensive research and secured multiple patents and patent applications related to vascular closure sealants. Because PEG sealants are purely synthetic, they carry no risk of transmission of viral pathogens or prions. They are also shown to result in less swelling and inflammation than fibrin sealants, are easy to apply, and report consistently good hemostatic results. “With our synthetic sealant strategy and the combined expertise and experience of our medical, technical and research team, we are well positioned to secure global commercialization of the MedClose,” says Rod Shipman, President and CEO of CPC of America. “We anticipate clinical investigation for multiple indications, which may include sealing of femoral arteriotomy closures, biopsies and vertebral bodies following transpedicular interventions. They may also include the sealing of difficult-to-control bleeding sites during surgery – such as cardiac, lung, liver, pancreas, and OB/GYN procedures”.